Chemistry:Concizumab
From HandWiki
Short description: Medication
| Clinical data | |
|---|---|
| Trade names | Alhemo |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Antihemorrhagic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H10004N1712O2046S46 |
| Molar mass | 145887.81 g·mol−1 |
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.[3] It is an anti-tissue factor pathway inhibitor.[3]
Concizumab was approved for medical use in Canada in March 2023.[5][6]
Medical uses
Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[3][4]
Society and culture
Names
Concizumab is the international nonproprietary name.[7]
References
- ↑ 1.0 1.1 "Alhemo". 11 July 2023. https://www.tga.gov.au/resources/auspmd/alhemo.
- ↑ "Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". 28 July 2023. https://www.tga.gov.au/resources/prescription-medicines-registrations/alhemo-novo-nordisk-pharmaceuticals-pty-ltd.
- ↑ 3.0 3.1 3.2 3.3 "Archived copy". https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/alhemo-en-product-monograph.pdf.
- ↑ 4.0 4.1 "Summary Basis of Decision for Alhemo". 31 May 2023. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1685635290781.
- ↑ 5.0 5.1 "Concizumab Product information". 10 March 2023. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102487.
- ↑ "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Retrieved 9 June 2023 – via Newswire.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information 27 (3). 2013.
 |  |
